The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective.
Bousquet J., Jutel M., Pfaar O., Fonseca JA., Agache I., Czarlewski W., Bachert C., Bergmann KC., Cruz AA., Klimek L., Kvedariene V., Larenas-Linnemann DE., Papadopoulos NG., Patella V., Regateiro FS., Scichilone N., Shamji MH., Sheikh A., Valovirta E., Ventura M-T., Zuberbier T.
Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many international or national practice guidelines have been produced, but the evidence-based method varies and they do not usually propose care pathways. The present article considers the possible role of mobile health in AIT for allergic rhinitis/asthma. There are no currently available validated biologic biomarkers that can predict AIT success, and mobile health biomarkers have some relevance. In the current article, the following aspects will be discussed: patient stratification for AIT, symptom-medication scores for the follow-up of patients, clinical trials, as well as the approach of the European Academy of Allergy and Clinical Immunology.